SCHEMBL2902815

SCHEMBL2902815

COc1cc2c(cc(CN3CCCN(Cc4cc5c(OC)c(OC)c(OC)cc5n4-c4ccccc4)CC3)n2-c2ccccc2)c(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
USP2 O75604 1/20 0.41
THRB P10828 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
ACHE P22303 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910549 0.80 KDM4E (0.47) SLC29A1KDM4ELMNAMEN1KMT2A
SCHEMBL2907404 0.76 KDM4E (0.42) SLC29A1KDM4ELMNAUSP2THRB
SCHEMBL27518752 0.73 ALDH1A1 (0.40) KDM4ELMNAMAPTKMT2AMTNR1A
SCHEMBL2909853 0.73 ALDH1A1 (0.50) SLC29A1KDM4ELMNAMAPTMEN1
SCHEMBL2905210 0.70 KDM4E (0.54) KDM4EMEN1KMT2APOLBALDH1A1
SCHEMBL2905193 0.70 ALDH1A1 (0.49) KDM4EMAPTMEN1KMT2AMTNR1A
SCHEMBL27518760 0.70 TNFRSF1A (0.40) KDM4ELMNAMAPTKMT2AMTNR1A
SCHEMBL2910647 0.70 SLC29A1 (0.46) SLC29A1KDM4ELMNAMEN1KMT2A
SCHEMBL2902539 0.68 KDM4E (0.43) KDM4ELMNAMAPTALOX15MTNR1A
SCHEMBL2910450 0.68 KDM4E (0.54) KDM4ETP53MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400510-B1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS KOWA CO (JP) 2010-08-18 EP disclosed
US-7135473-B2 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2006-11-14 US disclosed
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2004-03-25 US disclosed
EP-1400510-A1 CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6632810-B2 Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation KOWA CO., LTD. (JP) 2003-10-14 US disclosed
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups KOWA CO., LTD. (JP) 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058913-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 SLC29A1 1585/4885KDM4E 2052/4885LMNA 2954/4885
US-20030060461-A1 Cyclic diamine compound with condensed-ring groups HRH4, HRH3, HRH1 SLC29A1 1585/4885KDM4E 2052/4885LMNA 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.